Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:

NCT ID: NCT06037252 Recruiting - Obesity Clinical Trials

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Start date: September 21, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.

NCT ID: NCT06035874 Recruiting - Type 2 Diabetes Clinical Trials

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

B-LIFT
Start date: October 15, 2023
Phase: N/A
Study type: Interventional

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of individuals. NAFLD is intimately associated with insulin resistance and associated disorders, such as type 2 diabetes, metabolic syndrome and dyslipidemia. Bempedoic acid, an ATP-citrate lyase inhibitor, is recently approved for patients with dyslipidemia as a second line drug. Bempedoic acid reduces liver fat in mice model of NASH. Data regarding the effect of bempedoic acid on human liver fat are scarce. Therefore, the current study is planned to evaluate the effect of bempedoic acid versus standard treatment on liver and pancreatic fat content in patients with NAFLD

NCT ID: NCT06033508 Not yet recruiting - Type 2 Diabetes Clinical Trials

Effects of Whole-body Vibration Therapy on Type 2 Diabetic Patients With and Without Polyneuropathy

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to show how whole body vibration training practiced for 12 weeks affects the levels of inflammatory biomarkers such as C reactive protein (CRP) and, interleukin-6 (IL-6), in Type 2 diabetic patients (T2DM) with and without peripheral neuropathy.

NCT ID: NCT06028503 Recruiting - Type 2 Diabetes Clinical Trials

ACT Intervention for Type 2 Diabetes Management for Rural and Underserved Community

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this project is to examine the feasibility/acceptability of a one-day Acceptance and Commitment Therapy + Lifestyle Education group intervention paired with 12-weeks of Continuous Glucose Monitoring for patients with type 2 diabetes (T2D) living in rural communities. This study is being designed as a randomized control trial (RCT) comparing ACT+LE+CGM to LE+CGM to LE. The ultimate goal of this line of research is that a community-wide intervention of Acceptance and Commitment Therapy (ACT) with Continuous Glucose Monitoring (CGM) and Lifestyle Education (LE) will improve T2D outcomes in rural communities compared to CGM and LE, or LE alone. Our goal is to develop a scalable and sustainable program for diabetes management in rural areas that enables individual self-management and does not require extensive healthcare resources in an existing medical desert.

NCT ID: NCT06024928 Recruiting - Type 2 Diabetes Clinical Trials

Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes

AID-BIT
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to test the safety and feasibility of using an Automated Insulin Device (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration. Participants will be randomized to either the control group or the experimental group. If in the experimental group, the participant will use an insulin pump with Control-IQ Technology (Tandem Diabetes Care) for ten days. Researchers will compare the glycemic control of the experimental group to the control group.

NCT ID: NCT06016478 Recruiting - Type 2 Diabetes Clinical Trials

The Effect of 4 Weeks of L-Citrulline Supplementation on Macro- and Microvascular Function in Type 2 Diabetes

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of 4 weeks of Citrulline supplementation on macro- and microvascular function during acute hyperglycemia in middle-aged and older adults with type 2 diabetes.

NCT ID: NCT06013865 Recruiting - Type 2 Diabetes Clinical Trials

Empagliflozin Treatment in Kidney Transplant Recipients

SEKTR
Start date: April 5, 2024
Phase: Phase 4
Study type: Interventional

Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging. Patient death with existing kidney graft function occurs in about half of all recipients over time. This is primarily due to the development of cardiovascular disease in a patient population with multiple preexisting cardiac disease risk factors. There has been little progress in improving outcomes in this area for over two decades. Recent studies in chronic kidney disease (CKD) patients using SGLT2 inhibitors (SGLT2i), regardless of the presence of type 2 diabetes mellitus (T2DM), results in both kidney protective and cardiac protective impacts and improved patient outcomes. However, kidney transplant recipients (KTRs) were excluded from these clinical trials due to concerns that these agents promote infection, diminish graft function, and may alter immunosuppressive drug levels that are the mainstay of patient's transplant therapy. There are limited published data of SGLT2i treatment of selected KTRs.

NCT ID: NCT06010004 Active, not recruiting - Type 2 Diabetes Clinical Trials

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

ACHIEVE-J
Start date: September 28, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: - screening and lead-in period: up to 4 weeks - treatment period: 52 weeks, including 20 weeks of dose escalation, and - safety follow-up period: 2 weeks.

NCT ID: NCT06007404 Recruiting - Obesity Clinical Trials

Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents

Start date: September 6, 2023
Phase:
Study type: Observational

This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.

NCT ID: NCT06005987 Not yet recruiting - Type 2 Diabetes Clinical Trials

Mobile App Logging for Diabetes in Pregnancy

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

To determine the effect of using a mobile app versus paper logs on compliance and percentage in range blood sugars in monitoring blood sugar in pregnant women with diabetes.